Active Not RecruitingNCT06786325
Psilocybin and brain and clinical measures in opioid use disorder
About this title
Read the official source — NCT06786325Medication studyAges 18–60United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 7, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 36
- Sponsor
- Anna Rose Childress, Ph.D.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06786325
- Official title
Show the full official title
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Philadelphia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Anna Rose Childress, Ph.D.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
